RxDoctor Payments Data

Bryan Rabatic, MD

Radiation Oncology · Cincinnati, OHNPI 1669735023

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 43 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 16.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $402, 2.4 times the $169 reported in 2019.

$1,158in general payments, 2019–2025

Across 43 payments — averaging $26.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$190
  • Intuitive Surgical$133
  • AstraZeneca$123
  • E.r. Squibb & Sons, L.L.C.$122
  • Monteris Medical Corporation$111
  • Tactile Systems Technology Inc$71
  • plus $408 from 18 others
$45,759in research payments, 2019–2025

Across 2 payments — averaging $22,880 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • E.r. Squibb & Sons, L.L.C.$46K

What the payments were for

  • Food & beverage$1,158100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,158 in reported general payments places this provider in the 70th percentile of 255 radiation oncology providers in Ohio.

See all radiation oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$161,848
Medicare patients
201
Services billed
1,790

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone Hcl16$389
Dexamethasone11$135
Lidocaine Hcl ViscousLidocaine Hcl15$133
Fluconazole13$118

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →